Registro:

Referencias:

• Mocroft, A., Ledergerber, B., Katlama, C., et al, Decline in the AIDS and death rates in the EuroSIDA study: an observational study (2003) Lancet, 362, pp. 22-29
• Lundgren, J.D., Mocroft, A., The impact of antiretroviral therapy on AIDS and survival (2006) J HIV Ther, 2, pp. 36-38
• Mocroft, A., Phillips, A.N., Lundgren, J.D., HIV survival benefit associated with earlier antiviral therapy (2004) Ann Intern Med, 140, pp. 578-579
• Short-term risk of AIDS according to current CD4 cell cell count and viral load in antiretroviral drug-naïve individuals and in those treated in the monotherapy era (2004) AIDS, 18, pp. 51-58. , CASCADE Collaboration
• Egger, M., May, M., Chene, G., et al, Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies (2002) Lancet, 360, pp. 119-129
• Lau, B., Gange, S., Moore, R.D., Risk of non-AIDS related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4 cell+counts greater than 200 cells/mm3 (2007) J Acquir Immune Defic Syndr, 44, pp. 179-187
• Weber, R., Sabin, C.A., Friis-Møller, N., et al, Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study (2006) Arch Intern Med, 166, pp. 1632-1641
• Smit, C., Geskus, R., Walker, S., et al, Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion (2006) AIDS, 20, pp. 741-749
• Palella, F.J., Baker, R.K., Moorman, A.C., et al, Mortality in the highly active antiretroviral therapy era. Changing causes of death and disease in the HIV outpatient study (2006) J Acquir Immun Defic Syndr, 43, pp. 27-34
• Baker, J.V., Peng, G., Rapkin, J., et al, CD4 cell+count and risk of non-AIDS diseases following initial treatment for HIV infection (2008) AIDS, 22, pp. 841-848
• Liver-related deaths in persons infected with the human immunodeficiency virus (2006) Arch Intern Med, 166, pp. 1632-1641. , D:A:D Study Group
• Monforte, A., Abrams, D., Pradier, C., et al, HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies (2008) AIDS, 22, pp. 2143-2153
• El-Sadr, W.M., Lundgren, J.D., Neaton, J.D., et al, CD4+count-guided interruption of antiretroviral treatment (2006) N Engl J Med, 355, pp. 2283-2296. , for the Strategies for Management of Antiretroviral Therapy (SMART) Study Group
• Emery, S., Neuhaus, J.A., Phillips, A.N., et al, Major clinical outcomes in antiretroviral therapy (ART)-naïve participants and in those not receiving ART at baseline in the SMART Study (2008) J Infect Dis, 197, pp. 1133-1144. , for the Strategies for Management of Antiretroviral Therapy (SMART) Study Group
• Crum, N.F., Riffenburgh, R.H., Wegner, S., et al, Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early and late HAART (highly active antiretroviral therapy) eras (2006) J Acquir Immune Defic Syndr, 41, pp. 194-200
• Mocroft, A., Brettle, R., Kirk, O., et al, Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study (2002) AIDS, 16, pp. 1663-1671
• Baker, J.V., Peng, G., Rapkin, J., et al, Poor initial CD4 cell+recovery with antiretroviral therapy prolongs immune depletion and increases risk of AIDS and non-AIDS diseases (2008) JAIDS, 48, pp. 541-546
• Bautista-Arredondo, S., Gadsden, P., Harris, J.E., Bertozzi, S.M., Optimizing resource allocation for HIV/AIDS prevention programmes: an analytical framework (2008) AIDS, 22 (SUPPL. 1), pp. S67-S74
• (2008), pp. 129-159. , Joint United Nations Programme on HIV/AIDS (UNAIDS)., Treatment and care: unprecedented progress, remaining challenges. Report on the global AIDS epidemic; Chequer, P., Cuchi, P., Mazin, R., García Calleja, J.M., Access to antiretroviral treatment in Latin American countries and the Caribbean (2002) AIDS, 16 (SUPPL. 3), pp. S50-S57
• Bastos, F.I., Cáceres, C., Galvao, J., Veras, M.A., Castilho, E.A., AIDS in Latin America: assessing the current status of the epidemic and the ongoing response (2008) Int J Epidemiol, 37, pp. 729-737
• Rothman, K.J., Greenland, S., Lash, T.L., (2008) Modern Epidemiology, , 3rd ed, Philadelphia, PA, USA, Lippincott, Williams & Wilkins
• Robins, J., Gail, M.G., Lubin, J.H., More on 'biased selection of controls for case-control analysis of cohort studies' (1986) Biometrics, 42, pp. 293-299
• Knol, M.J., Vandenbroucke, J.P., Scott, P., Egger, M., What do case-control studies estimate? Survey of methods and assumptions in published case-control research (2008) Am J Epidemiol, 168, pp. 1073-1081
• McQueen, M.J., Hawken, S., Wang, X., et al, Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study (2008) Lancet, 372, pp. 224-233
• Kuller, L.H., Tracy, R., Belloso, W.H., et al, Inflammation and coagulation biomarkers and mortality in patients with HIV infection (2008) PLoS Med, 5, pp. e203
• Mu, H., Chai, H., Lin, P.H., Yao, Q., Chen, C., Current update on HIV-associated vascular disease and endothelial dysfunction (2007) World J Surg, 31, pp. 632-643
• Mehta, N., Reilly, M., Atherosclerotic cardiovascular disease risk in the HAART-treated HIV-1 population (2005) HIV Clin Trials, 6, pp. 5-24
• Stein, J.H., Klein, M.A., Bellehumeur, J.L., et al, Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction (2001) Circulation, 104, pp. 257-262
• Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration (2008) Lancet, 371, pp. 1417-1426. , D:A:D Study Group
• Thein, H.H., Yi, Q., Dore, G.J., Krahn, M.D., Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis (2008) AIDS, 22, pp. 1979-1991
• Bottecchia, M., Garcia-Samaniego, J., Soriano, V., The implications of antiviral drugs with activity against hepatitis B virus and HIV (2007) Curr Opin Infect Dis, 20, pp. 621-628
• Puoti, M., Torti, C., Bruno, R., Filice, G., Carosi, G., Natural history of chronic hepatitis B in co-infected patients (2006) J Hepatol, 44 (SUPPL.), pp. S65-S70
• Class of antiretroviral drugs and the risk of myocardial infarction (2007) N Engl J Med, 356, pp. 1723-1735. , DAD Study Group
• Moore, R.D., Gebo, K.A., Lucas, G.M., Keruly, J.C., Rate of comorbidities not related to HIV infection or AIDS among HIV-infected patients, by CD4 cell cell count and HAART use status (2008) Clin Infect Dis, 47, pp. 1102-1104
• Crabtree-Ramirez, B., Gómez Palacio, M., Rodríguez Rivera, V., Reyes-Terán, G., Baseline characteristics of HIV-infected patients attending a National Institute of Health in Mexico City: evidence of late detection of HIV infection and the urgent need for efficient. Voluntary Counseling and Testing (VCT) programs. Mexico DF, Mexico, August 2008. [Abstract THPE0244]

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------